Table 1. Patient’s laboratory data at the disease onset.
MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; CRP, C-reactive protein; TP, total protein; Alb, albumin; BUN, blood urea nitrogen; CRE, creatinine; UA, uric acid; T-Bil, total bilirubin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; LDH, lactate dehydrogenase; gGTP, gamma-glutamyl transpeptidase; Na, sodium; K, potassium; Cl, chloride; Ca, calcium; PT, prothrombin time; PT activity, prothrombin time activity; PT-INR, prothrombin time-international normalized ratio; APTT, activated partial thromboplastin time; FIB, fibrinogen; ATIII, antithrombin III
| Count blood cells | Reference range | ||
| WBC | 13,640 | /µL | 3,300-8,600 |
| Band cells | 1.0 | % | 2.0-10.0 |
| Segmented cells | 95.0 | % | 50.0-70.0 |
| Eosinophil | 0.0 | % | 1.0-5.0 |
| Basophil | 0.0 | % | 0.0-1.0 |
| Lymphocyte | 2.0 | % | 20.0-40.0 |
| Monocyte | 1.0 | % | 1.0-6.0 |
| Metamyelocyte | 1.0 | % | 0.0 |
| Myelocyte | 0.0 | % | 0.0 |
| Promyelocyte | 0.0 | % | 0.0 |
| RBC | 172 × 104 | /µL | 435-555 |
| Hemoglobin | 5.7 | g/dL | 13.7-16.8 |
| Hematocrit | 16.5 | % | 40.7-50.1 |
| MCV | 95.9 | fL | 83.6-98.2 |
| MCH | 33.1 | pg | 27.5-33.2 |
| MCHC | 34.5 | % | 31.7-35.3 |
| Platelet | 18.7 × 104 | /µL | 15.8-34.8 |
| Biochemistry | |||
| CRP | 9.51 | mg/dL | <0.14 |
| TP | 4.3 | g/dL | 6.6-8.1 |
| Alb | 1.1 | g/dL | 4.1-5.1 |
| BUN | 11.0 | mg/dL | 8-20 |
| CRE | 0.42 | mg/dL | 0.65-1.07 |
| UA | 2.5 | mg/dL | 3.7-7.8 |
| T-Bil | 0.5 | mg/dL | 0.4-1.5 |
| AST | 29 | U/L | 13-30 |
| ALT | 29 | U/L | 10-42 |
| ALP | 106 | U/L | 38-113 |
| LDH | 200 | U/L | 124-222 |
| gGTP | 9 | U/L | 13-64 |
| Na | 128 | mmol/L | 138-145 |
| K | 3.4 | mmol/L | 3.6-4.8 |
| Cl | 97 | mmol/L | 101-108 |
| Ca | 9.0 | mg/dL | 8.8-10.1 |
| Coagulation/fibrinolysis | |||
| PT | 13.0 | sec | 9.3-12.5 |
| PT activity | 79.5 | % | 80.7-125.2 |
| PT-INR | 1.14 | 0.85-1.13 | |
| APTT | >100.0 | sec | 24.0-34.0 |
| FIB | 144 | mg/dL | 200-400 |
| ATIII | 49.1 | % | 80.0-130.0 |
| D-Dimer | 6.8 | µg/mL | <1.0 |
| Others | |||
| vWF activity | 296 | % | 60-170 |
| vWF Ag | 204 | % | 50-155 |
| Lupus anticoagulant | 1.2 | 0.0-1.2 | |
| b2GPIAb | ≤1.2 | U/mL | <3.5 |
| APL panel | |||
| Anti-CL IgG | 3.8 | U/mL | <20 |
| Anti-CL IgM | 1.1 | U/mL | <20 |
| Anti-GP1 IgG | <6.4 | U/mL | <20 |
| Anti-GP1 IgM | <1.1 | U/mL | <20 |